Exosens Shares Drop 2.91% to €63.30, Bucking the Trend of an Euphoric CAC 40
Exosens shares fell by 2.91% to €63.30 in mid-session trading on Wednesday, while the CAC 40 index rose by 3.11% to 8,312.84 points. The company, specializing in night vision and imaging technology for defense, is moving against the upward trend of European markets, which are buoyed by geopolitical easing in the Middle East. However, the stock still maintains a year-on-year gain of 74.38%.
European indices surged on Wednesday amid diplomatic rapprochement between Washington and Tehran. The SBF 120 is up 3.05% and the DAX has gained 2.58%. Brent crude has dropped nearly 8.6% to $100.44, as the market removes some of the war premium built into prices. Exosens stands out with its isolated decline, with no specific news identified for the day. The geopolitical relaxation mechanically weighs on the sentiment around defense stocks, a sector that encompasses most of the group's activities. As a reminder, at the end of April, the company reported a 19.7% increase in first-quarter revenue to €122.6 million, driven by demand for night vision for defense.
Below the 50-Day Average, at the Lower End of the Bollinger Bands
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
At €63.30, Exosens has moved below its 50-day moving average of €64.33 after testing it for several sessions. The price is in the lower part of the Bollinger Bands, about 2.5% above the lower boundary set at €61.76. The RSI at 53 remains neutral, with no overbought or oversold signals. The 200-day moving average, at €50.71, remains well behind, reflecting the stock's fundamentally upward trajectory. The 2025 guidance communicated during the first nine months' earnings report targets revenue growth at the upper end of the 15-20% range and adjusted EBITDA growth at the lower end of the 20-25% range. Technical support is located at €57.50. The next key date on the calendar is the general meeting on May 22, 2026.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
